Dyadic to Present at Industry and Investor Events in October
29 September 2023 - 10:30PM
Dyadic International, Inc. (“Dyadic”, or the “Company”) (NASDAQ:
DYAI), a global biotechnology company focused on building
innovative microbial platforms to address the growing demand for
global protein bioproduction and unmet clinical needs for
effective, affordable and accessible biopharmaceutical products for
human and animal health, and alternative proteins for food,
nutrition and wellness, today announced that its management will be
presenting at the following industry and investor events during the
month of October:
Enzyme Engineering XXVII, October 1-6, 2023Park
Royal Hotel, SingaporeDr. Ronen Tchelet, Chief Scientific
Officer“The use of in silico analysis to engineer the best
immunogenic epitope and produce the corresponding prophylactic
antigen-based vaccines with C1 production platform in order to
rapidly respond to viral pandemics” Wednesday, October 4, 2023,
11:00 AM – 11:30 AM
LD Mirco Main Event XVI, October 3-5, 2023Luxe
Sunset Blvd Hotel, Los Angeles, CAMark Emalfarb, President, and
Chief Executive Officer “Next Generation Proteins for World Health,
Nutrition and Wellness” Wednesday, October 4, 2023, 8:00 AM – 8:25
AM
World Vaccine Congress Europe, October 16-19,
2023Fira de Barcelona Montjuic, Barcelona, SpainMark Emalfarb,
President, and Chief Executive Officer“Rapid development and
flexible scale manufacturing of complex recombinant proteins and
antigens including ferritin nanoparticles for seasonal and pandemic
influenza vaccines” Wednesday, October 18, 2023, 11:45 AM – 12:00
PM
If you would like to connect with Dyadic’s
management at any of the events, you may request a one-on-one
meeting at jlavalley@dyadic.com.
About Dyadic International,
Inc.
Dyadic International, Inc. is a global
biotechnology company focused on building innovative microbial
platforms to address the growing demand for global protein
bioproduction and unmet clinical needs for effective, affordable
and accessible biopharmaceutical products for human and animal
health, and alternative proteins for food, nutrition and
wellness.
Dyadic’s gene expression and protein production
platforms are based on the highly productive and scalable fungus
Thermothelomyces heterothallica (formerly Myceliophthora
thermophila). Our lead technology, C1-cell protein production
platform, is based on an industrially proven microorganism (named
C1), which is currently used to speed development, lower production
costs, and improve performance of biologic vaccines and drugs at
flexible commercial scales for the human and animal health markets.
Dyadic has also developed the Dapibus™ filamentous fungal
based microbial protein production platform to enable the rapid
development and large-scale manufacture of low-cost proteins,
metabolites, and other biologic products for use in
non-pharmaceutical applications, such as food, nutrition, and
wellness.
With a passion to enable our partners and
collaborators to develop effective preventative and therapeutic
treatments in both developed and emerging countries, Dyadic is
building an active pipeline by advancing its proprietary microbial
platform technologies, including our lead asset DYAI-100 COVID-19
vaccine candidate, as well as other biologic vaccines, antibodies,
and other biological products.
To learn more about Dyadic and our commitment to
helping bring vaccines and other biologic products to market
faster, in greater volumes and at lower cost, please visit
http://www.dyadic.com.
Safe Harbor
Regarding Forward-Looking
Statements
This press release contains forward-looking
statements within the meaning of Section 27A of the Securities Act
of 1933 and Section 21E of the Securities Exchange Act of 1934,
including those regarding Dyadic International’s expectations,
intentions, strategies, and beliefs pertaining to future events or
future financial performance, such as the success of our clinical
trial and interest in our protein production platforms, our
research projects and third-party collaborations, as well as the
availability of necessary funding. Actual events or results may
differ materially from those in the forward-looking statements
because of various important factors, including those described in
the Company’s most recent filings with the SEC. Dyadic assumes no
obligation to update publicly any such forward-looking statements,
whether because of new information, future events or otherwise. For
a more complete description of the risks that could cause our
actual results to differ from our current expectations, please see
the section entitled “Risk Factors” in Dyadic’s annual reports on
Form 10-K and quarterly reports on Form 10-Q filed with the SEC, as
such factors may be updated from time to time in Dyadic’s periodic
filings with the SEC, which are accessible on the SEC’s website and
at www.dyadic.com.
Contact:
Dyadic International, Inc.Ping W. RawsonChief
Financial OfficerPhone: (561) 743-8333Email: ir@dyadic.com
Dyadic (NASDAQ:DYAI)
Historical Stock Chart
From Apr 2024 to May 2024
Dyadic (NASDAQ:DYAI)
Historical Stock Chart
From May 2023 to May 2024